Under construction – not a live service
Sign in
Taking people in CanadaNo phase

Exercise Timing Compared in Adults With Type 1 Diabetes

Tests aerobic exercise before breakfast against exercise after breakfast in adults with type 1 diabetes.

Plain-language title generated from the registry record
Registry title: Fasted Exercise Training in Type 1 Diabetes (FED-T1D)

Key facts

Where
Edmonton, CanadaSee the site

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 55 years old?

Source: NCT06748963, who can take part

Where in Canada

  • University of AlbertaEdmonton, CanadaTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
University of Alberta
Trial code
NCT06748963
Record updated
8 May 2026
Original description
This study compares aerobic exercise training performed before breakfast (i.e., in the fasted state) to similar training performed after breakfast in people with type 1 diabetes. Training will take place over 12 weeks.Read full original descriptionShow less

Exercise Training Before (Fasted) Versus After (Fed) Breakfast in Type 1 Diabetes

This study compares aerobic exercise training performed before breakfast (i.e., in the fasted state) to similar training performed after breakfast in people with type 1 diabetes. Training will take place over 12 weeks.

Inclusion: Clinical diagnosis of type 1 diabetes for 5 or more years; Treatment using an insulin pump with no change in treatment modality for > 2 continuous months and willing to share CGM data with the research team. Insulin delivery can be managed using either manual open-loop system (non-AID) or a hybrid closed loop (AID) systems; Using rapid (e.g., Aspart, Lispro or Glulisine) or ultra-rapid (e.g., FiAsp) acting insulin analogs; HbA1c 7.0-9.9%; Have BMI of 25 kg/m2 or above; Have waist circumference associated with central obesity/metabolic syndrome as per Diabetes Canada definition; 94cm for males of European, Sub-Saharan African, Eastern Mediterranean and Middle Eastern descent; 90cm for males of South Asian, Chinese, Japanese, South and Central American descent; 80cm for females; No history of stroke, myocardial infarction, or coronary artery disease; Not wearing implantable device such as a pacemaker, neurostimulators, aneurysm clips, metal fragments, epicardial electrodes, cochlear implants, magnetic ocular implants, penile implants, magnetic tissue expander, some types of breast implants, magnetic orthopedic implants, magnetic dental implants, hearing Aids, intravascular implants, for example VCI filters, coils, stents, cardiac septum implants, ventricular bypass devices; Use a CGM in routine diabetes management.

Exclusion: Major complication within the previous 3 months (e.g., severe hypoglycemia requiring assistance, diabetic ketoacidosis, or cardiovascular event); Use of an injection-based insulin therapy (ex. multiple daily injections or combined pump and injection-based delivery); Restriction in aerobic or resistance exercise due to significant diabetes complications (e.g., severe peripheral neuropathy, active proliferative retinopathy, etc.) or other type of limitations (e.g., orthopedic, severe arthritis, etc.); Uncontrolled hypertension (e.g., blood pressure >160 mmHg systolic or >100 mmHg diastolic); Implanted device, material, or having a condition contraindicated to MRI; Ongoing pregnancy or breastfeeding; Inability to give consent.

ClinicalTrials.gov NCT06748963